inebilizumab

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Stem definition	Drug id	CAS RN
humanized origin	5397	1299440-37-1

Stem definition

Drug id

CAS RN

humanized origin

5397

1299440-37-1

Description:

Molecule	Description
Molfile Synonyms: inebilizumab inebilizumab-cdon uplizna 16C4-aFuc A-fucosylated anti-CD19 antibody anti-CD19 MAb-Viela-Bio MEDI-551 MT-0551	Inebilizumab-cdon is a CD19-directed humanized afucosylated IgG1 monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension culture. The precise mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD is unknown but is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis (ADCC). Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

inebilizumab
inebilizumab-cdon
uplizna
16C4-aFuc
A-fucosylated anti-CD19 antibody
anti-CD19 MAb-Viela-Bio
MEDI-551
MT-0551

Inebilizumab-cdon is a CD19-directed humanized afucosylated IgG1 monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension culture. The precise mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD is unknown but is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis (ADCC).

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Date	Agency	Company
June 11, 2020	FDA	VIELA BIO
March 23, 2021	PMDA	Mitsubishi Tanabe Pharma Corporation
April 25, 2022	EMA	Horizon Therapeutics Ireland DAC

Date

Agency

Company

Orphan

June 11, 2020

FDA

VIELA BIO

March 23, 2021

PMDA

Mitsubishi Tanabe Pharma Corporation

April 25, 2022

EMA

Horizon Therapeutics Ireland DAC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuromyelitis optica spectrum disorder	50.28	44.12	8	330	1482	90626627

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Neuromyelitis optica spectrum disorder

50.28

44.12

330

1482

90626627

Pharmacologic Action:

Source	Code	Description
ATC	L04AG10	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Monoclonal antibodies
FDA MoA	N0000191422	CD19-directed Antibody Interactions
FDA EPC	N0000194013	CD19-directed Cytolytic Antibody
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35705	immunosuppressive agent

Source

Code

Description

ATC

L04AG10

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Monoclonal antibodies

FDA MoA

N0000191422

CD19-directed Antibody Interactions

FDA EPC

N0000194013

CD19-directed Cytolytic Antibody

CHEBI has role

CHEBI:35610

antineoplastic agent

CHEBI has role

CHEBI:35705

immunosuppressive agent

Disease	Relation	SNOMED_ID	DOID
Neuromyelitis optica	indication	25044007	DOID:8869
Tuberculosis	contraindication	56717001
Viral hepatitis type B	contraindication	66071002	DOID:2043

Disease

Relation

SNOMED_ID

DOID

Neuromyelitis optica

indication

25044007

DOID:8869

Tuberculosis

contraindication

56717001

Viral hepatitis type B

contraindication

66071002

DOID:2043

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD19	Surface antigen	P15391	CD19_HUMAN	ANTIBODY BINDING	Kd	9.80		IUPHAR	DRUG LABEL
Low affinity immunoglobulin gamma Fc region receptor III-A	Membrane receptor	P08637	FCG3A_HUMAN	ANTIBODY BINDING	Kd	7.11		SCIENTIFIC LITERATURE

Target

Class

Pharos

UniProt

Action

Type

Activity value
(-log[M])

Mechanism
action

Bioact source

MoA source

B-lymphocyte antigen CD19

Surface antigen

P15391

CD19_HUMAN

ANTIBODY BINDING

9.80

IUPHAR

DRUG LABEL

Low affinity immunoglobulin gamma Fc region receptor III-A

Membrane receptor

P08637

FCG3A_HUMAN

ANTIBODY BINDING

7.11

SCIENTIFIC LITERATURE

External reference:

ID	Source
D11757	KEGG_DRUG
74T7185BMM	UNII
4039495	VANDF
4039496	VANDF
C4519594	UMLSCUI
CHEBI:754166	CHEBI
CHEMBL2109334	ChEMBL_ID
DB12530	DRUGBANK_ID
9985	INN_ID
C000609745	MESH_SUPPLEMENTAL_RECORD_UI
7992	IUPHAR_LIGAND_ID
879883007	SNOMEDCT_US
879892005	SNOMEDCT_US
335069	MMSL
38531	MMSL
d09575	MMSL
018404	NDDF
2373950	RXNORM

Source

D11757

KEGG_DRUG

74T7185BMM

UNII

4039495

VANDF

4039496

VANDF

C4519594

UMLSCUI

CHEBI:754166